-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

503.O1.6 503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts And Biosamples

Symposia: Clonal Hematopoiesis, Aging and Inflammation Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, clinical trials, Biological therapies, Antibody Therapy, Acute Myeloid Malignancies, AML, adult, CHIP, Translational Research, elderly, Clinical Research, genomics, bioinformatics, hematopoiesis, Diseases, Therapies, Biological Processes, Myeloid Malignancies, Technology and Procedures, molecular biology, Study Population, multi-systemic interactions, Human, omics technologies
Monday, December 12, 2022: 4:30 PM-6:00 PM
252-254 (Ernest N. Morial Convention Center)
Moderators:
Siddhartha Jaiswal, MD, Stanford University and Peter G. Miller, MD, PhD,
Disclosures:
Miller: Foundation Medicine, Inc: Consultancy.
The abstracts presented in this session utilize data from human cohorts and samples to advance our understanding of the causes and consequences of Clonal Hematopoiesis.
4:30 PM

Niels Asger Jakobsen, BM BCh MRCP1,2,3*, Sven Turkalj1,3*, Bilyana Stoilova, PhD1,4*, Marlen Metzner, MSc1,3*, Rachel Moore, BA1*, Batchimeg Usukhbayar1*, Mirian Angulo Salazar, MSc1*, Alison Kennedy, MSc1,5*, Simon Newman6,7*, Benjamin Kendrick6,7*, Adrian Taylor6,7*, Rasheed Afinowi-Luitz6*, Roger Gundle6,7*, Bridget Watkins7*, Kim Wheway7*, Debra Beazley7*, Andrew Carr, ChM DSc FRCS FMedSci7* and Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath1,2,3

1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
2Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
3Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
4Department of Paediatrics, University of Oxford, Oxford, United Kingdom
5Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
6Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
7Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom

4:45 PM

Lachelle D. Weeks, MD, PhD1,2,3, Abhishek Niroula, PhD1,4,5*, Donna S. Neuberg, ScD6, Waihay J. Wong, MD, PhD7*, R. Coleman Lindsley3,8, Marlise R. Luskin, MD1,3, Nancy Berliner, MD3,9, Richard M. Stone, MD3,10, Daniel J DeAngelo, MD, PhD3,10, Robert J Soiffer, MD3,11,12, Md Mesbah Uddin, MSc, PhD13,14*, Christopher J. Gibson, MD1,3, Alexander G. Bick, MD, PhD15*, Gabriel K. Griffin, MD16,17, Siddhartha Jaiswal, MD18, Luca Malcovati, MD19,20, Pradeep Natarajan, MD13,21* and Benjamin L. Ebert, MD, PhD1,5,22,23,24

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Center for Prevention of Progression, Dana-Farber Cancer Institute, Boston, MA
3Department of Medicine, Harvard Medical School, Boston, MA
4Department of Laboratory Medicine, Lund University, Lund, Sweden
5Broad Institute of MIT and Harvard University, Cambridge, MA
6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
7Department of Pathology, Brigham and Women's Hospital, Boston, MA
8Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
10Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
11Division of Stem Cell Transplant and Cellular Therapies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
12Center for Prevention of Progression, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
13Cardiovascular Disease Research Center, Massachusetts General Hospital, Boston, MA
14Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA
15Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
16Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
17Department of Pathology, Brigham and Women's Hospital, Newton, MA
18Department of Pathology, Stanford University, Stanford, CA
19Department of Molecular Medicine, University of Pavia, Pavia, Italy
20Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy
21Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA
22Harvard Medical School, Boston, MA
23Howard Hughes Medical Institute, Boston, MA
24Dana-Farber Cancer Institute, Boston, MA

5:00 PM

Hidetaka Uryu1*, Koichi Saeki, PhD2*, Jyoti Nangalia, MBBChir3, Michael Spencer Chapman, MBBS4*, Li Zhao, PhD5*, Joanne I. Hsu, MD, PhD6,7,8*, Carlos E. Bueso-Ramos, MD, PhD9,10,11, Shujuan Chen12*, Hui Yang, MD, PhD13, Hagop Kantarjian, MD14, Courtney D. DiNardo, MD, MSCE13, Naval Daver, MD13, Simona Colla, PhD15*, Irene Ganan-Gomez, PhD13, Jianhua Zhang, PhD5*, Xingzhi Song, PhD16*, Erika Thompson, MS17*, Hongli Tang17*, Robert Z. Orlowski, MD, PhD18, Richard E Champlin, MD19, Muzaffar H Qazilbash, MD19, Elizabeth J Shpall, MD19, Guillermo Garcia-Manero, MD20, Hiroshi Haeno, PhD.21*, Andrew Futreal, PhD12* and Koichi Takahashi, MD, PhD22

1Leukemia Department, The UNIVERSITY of TEXAS, M.D. Anderson, Houston, TX
2The University of Tokyo, Graduate School of Frontier Sciences, Kashiwa, Japan
3Wellcome Sanger Institute, Saffron Walden, ENG, United Kingdom
4Department of Haematology, Department of Haematology, London, ENG, United Kingdom
5Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
6Medical Scientist Training Program, Baylor College of Medicine, Houston
7Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston
8Harvard Medical School, Boston, MA
9Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
11Leukemia Department, MD Anderson Cancer Center, Houston, TX
12Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
14Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
15Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
16Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX
17Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
18Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
19Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
20Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
21Division of Integrated Research Research, Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan
22Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

5:15 PM

Niklas Landberg, MD, PhD1*, Thomas Koehnke, MD, PhD2, Yusuke Nakauchi, MD, PhD2, Amy Fan2*, Daiki Karigane, MD, PhD2*, Daniel Thomas, MD, PhD3 and Ravindra Majeti, MD, PhD2

1Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Lund, Skåne, Sweden
2Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA
3Adelaide Medical School, University of Adelaide,, The University of Adelaide, Adelaide, SA, Australia

5:30 PM

Janghee Woo, MD, PhD1, Darlene Lu, PhD1*, Andrew Lewandowski, PhD1*, Paul M. Ridker, MD, MPH2*, Benjamin L. Ebert, MD, PhD3 and David Steensma, MD1*

1Novartis Institutes for BioMedical Research, Cambridge, MA
2Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
3Dana-Farber Cancer Institute, Boston, MA

5:45 PM

Zoe McQuilten, MBBS, PhD1,2*, Nicholas C. Wong, BSc (Hons) PhD3*, Anna Leichter, BSc4*, Le T.P. Thao, PhD5*, James Phung, BSc5*, Andrew J Murphy, BSc PhD6*, Moeen Riaz, BS PhD5*, Robert Sebra, PhD7*, Alexander G. Bick, MD, PhD8*, John J. McNeil, MBBS PhD5*, Rory Wolfe, PhD5*, Robyn L. Woods, BSc (Hons) PhD5*, Paul Lacaze, PhD5*, Erica M. Wood, MBBS, FRACP, FRCPA9,10 and David J. Curtis, MBBS, PhD11

1School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
2Monash Health, Melbourne, Australia
3Monash Bioinformatics Platform, Monash University, Melbourne, Australia
4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
5Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
6Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Australia
7Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
8Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
9Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia
10Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
11Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia

*signifies non-member of ASH